Christian Takayama
Family Medicine · Los Angeles, CANPI 1992968648
Payments from drug & device makers
Across 505 payments — averaging $24.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$5K
- Viiv Healthcare Company$4K
- Johnson & Johnson$1K
- Merck$1K
- Janssen Products, LP$294
- GSK$239
- plus $569 from 10 others
What the payments were for
- Consulting fees$1,84015%
- Food & beverage$10,39282%
- Education$3853%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 209 | $4,817 |
| Viiv Healthcare Company | 110 | $4,274 |
| Johnson & Johnson(2 entities) | 89 | $1,311 |
| Merck | 55 | $1,114 |
| Janssen Products, LP | 3 | $294 |
| GSK | 12 | $239 |
| Napo Pharmaceuticals Inc | 9 | $203 |
| AbbVie | 7 | $161 |
| Dynavax Technologies Corporation | 4 | $76 |
| Theratechnologies Inc. | 1 | $25 |
| EMD Serono, Inc. | 1 | $24 |
| Hologic Sales And Service, LLC | 1 | $21 |
| Novo Nordisk | 1 | $18 |
| Exact Sciences | 1 | $15 |
| Celltrion, Inc. | 1 | $13 |
| Idorsia Pharmaceuticals US Inc | 1 | $13 |
How this compares
$12,618 in reported general payments places this provider in the 95th percentile of 10,533 family medicine providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| SymtuzaDarunavir/Cob/Emtri/Tenof Alaf | 55 | $278,172 |
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 64 | $244,948 |
| TivicayDolutegravir Sodium | 62 | $139,646 |
| JulucaDolutegravir/Rilpivirine | 16 | $74,042 |
| CabenuvaCabotegravir/Rilpivirine | 11 | $54,614 |
| OdefseyEmtricitab/Rilpiviri/Tenof Ala | 14 | $49,912 |
| OzempicSemaglutide | 17 | $15,767 |
| ValacyclovirValacyclovir Hcl | 12 | $426 |
| Gabapentin | 25 | $406 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 22 | $387 |
| Testosterone | 12 | $270 |
| Testosterone Cypionate | 11 | $228 |
| Ibuprofen | 28 | $204 |
| Fluoxetine Hcl | 24 | $201 |
| Alprazolam | 21 | $133 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Janssen Products, LPSymtuza | $294 | $278,17255 claims |
| Viiv Healthcare CompanyTivicay, Juluca, Cabenuva | $4,274 | $268,30289 claims |
| GileadBiktarvy | $4,817 | $244,94864 claims |
| Novo NordiskOzempic | $18 | $15,76717 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 10,533 family medicine providers in California.
Other family medicine in Los Angeles
- Albert NassirLos Angeles$5.7M
- Nader SobhLos Angeles$4.1M
- Alexander RivkinLos Angeles$2.8M
- Pamela KushnerLos Angeles$1.2M
- Scott HowellLos Angeles$793K
- Amina HaggagNorthridge$112.8M
- Steven ReynoldsLong Beach$53M
- Rizwana MohseniLake Forest$26.7M
- Daniel JohnsonSan Diego$15.7M
- Stacey LayleSan Diego$14.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.